You can spend time nit picking semantics or my poo
Post# of 30027
Posted On: 01/21/2016 9:58:32 PM
You can spend time nit picking semantics or my poor typing abilities, but you're missing the point.
I realize this doesn't solve AMBS cash issues. The question everyone is asking is why did GC do this deal- what is in it for AMBS? This is what I was addressing. Companies out-license drugs (or other technologies) all the time long before they are approved. Phase 2 drugs often get licensed with several years to go before they are approved. I believe AVDX is in talks to receive a substantial sum of upfront cash to license OvaDX as this is the ONLY logical reason that makes any sense why AMBS did this deal.
An up front payment of 20 million dollars is totally in the range of what would be expected in this case. Suppose OvaDX is approved- how much is it worth than? There is only one other Ovarian cancer test, CA-125 and it does 2 billion a year in sales.
I realize this doesn't solve AMBS cash issues. The question everyone is asking is why did GC do this deal- what is in it for AMBS? This is what I was addressing. Companies out-license drugs (or other technologies) all the time long before they are approved. Phase 2 drugs often get licensed with several years to go before they are approved. I believe AVDX is in talks to receive a substantial sum of upfront cash to license OvaDX as this is the ONLY logical reason that makes any sense why AMBS did this deal.
An up front payment of 20 million dollars is totally in the range of what would be expected in this case. Suppose OvaDX is approved- how much is it worth than? There is only one other Ovarian cancer test, CA-125 and it does 2 billion a year in sales.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼